Pacira Files Definitive Proxy for Contested Board Election, Seeks Shareholder Approval for Dilutive Equity Plans Amidst Activist Pressure

summarizeSummary

Pacira BioSciences has filed its definitive proxy statement, confirming a contested board election with activist investor DOMA Perpetual, who is advocating for a company sale. The company is also seeking approval for significant share increases for its equity incentive plans and has detailed changes to executive compensation following a low Say-on-Pay vote.

check_boxKey Events

• Contested Board Election Confirmed

  The definitive proxy statement confirms a contested election for three Class III director seats at the upcoming annual meeting on June 9, 2026, with activist investor DOMA Perpetual Capital Management LLC nominating its own slate of candidates.

• Activist Investor Pushes for Company Sale

  DOMA Perpetual, a 7.5% beneficial owner, is actively advocating for a formal sales process for Pacira BioSciences and has previously threatened legal action against the board.

• Significant Share Authorization Requested

  Shareholders are asked to approve an increase of 2,200,000 shares for the 2011 Stock Incentive Plan (approximately 5.6% potential dilution) and 800,000 shares for the 2014 Employee Stock Purchase Plan (approximately 2.03% potential dilution).

• Executive Compensation Reforms After Low Say-on-Pay Vote

  In response to a 39.5% Say-on-Pay approval in 2025, the company introduced Performance Share Units (PSUs) for 2026 executive grants and applied negative discretion to 2025 annual incentive bonuses.

auto_awesomeAnalysis

Pacira BioSciences has filed its definitive proxy statement for its upcoming annual meeting, confirming a contested election for three board seats with activist investor DOMA Perpetual Capital Management LLC. DOMA, holding a 7.5% stake, is actively pushing for a formal sales process for the company and has previously threatened legal action against the board. This proxy contest introduces significant uncertainty regarding the company's future strategic direction and leadership. Additionally, the company is seeking shareholder approval for a substantial increase in its equity incentive plans, including 2,200,000 new shares for its 2011 Stock Incentive Plan (approximately 5.6% dilution) and 800,000 shares for its Employee Stock Purchase Plan (approximately 2.03% dilution). These requests, while framed for talent retention and growth, represent notable potential dilution. The filing also details the company's response to a very low 39.5% Say-on-Pay vote in 2025, including the introduction of Performance Share Units (PSUs) and adjustments to executive compensation practices, indicating a direct effort to address shareholder dissatisfaction. Investors should closely monitor the outcome of the proxy vote, as it could significantly impact the company's governance, capital allocation, and potential strategic alternatives.